Trial Profile
First-in-human, 9-period, randomized, double-blinded, placebo-controlled, crossover, ascending dose study of GA 021
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Nov 2015
Price :
$35
*
At a glance
- Drugs GAL 021 (Primary)
- Indications Respiratory insufficiency
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Galleon Pharmaceuticals
- 26 Nov 2015 New trial record